{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:40:23Z","timestamp":1779889223832,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06031-0","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T21:02:12Z","timestamp":1729630932000},"page":"5651-5661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-4839","authenticated-orcid":false,"given":"Sunil","family":"Lakhwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol Dachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gonz\u00e1lez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gironella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Granell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Abella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Garc\u00eda-Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ramila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Krsnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Casado Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Amutio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"L\u00f3pez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Alt\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1ngeles","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lopez-Anglada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alonso Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9 Creixenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Teodoro","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"6031_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"6031_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12307-011-0086-3","volume":"4","author":"K Noonan","year":"2011","unstructured":"Noonan K, Borrello I (2011) The immune microenvironment of myeloma. Cancer Microenviron 4:313\u2013323","journal-title":"Cancer Microenviron"},{"key":"6031_CR3","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ, Martinet L (2020) Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136:2731\u20132740","journal-title":"Blood"},{"key":"6031_CR4","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412\u20135417","journal-title":"Blood"},{"key":"6031_CR5","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss BM, Abadie J, Verma P et al (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418\u20135422","journal-title":"Blood"},{"key":"6031_CR6","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125:3049\u20133058","journal-title":"Blood"},{"key":"6031_CR7","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clml.2014.12.003","volume":"15","author":"P V\u0161iansk\u00e1","year":"2015","unstructured":"V\u0161iansk\u00e1 P, \u0158\u00edhov\u00e1 L, Varmu\u017eov\u00e1 T et al (2015) Analysis of B-cell subpopulations in monoclonal gammopathies. Clin Lymphoma Myeloma Leuk 15:e61\u2013e71","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6031_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2014.110","volume":"28","author":"E Kastritis","year":"2014","unstructured":"Kastritis E, Zagouri F, Symeonidis A et al (2014) Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 28:2075\u20132079","journal-title":"Leukemia"},{"key":"6031_CR9","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","volume":"32","author":"JLJ Heaney","year":"2018","unstructured":"Heaney JLJ, Campbell JP, Iqbal G et al (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 32:1727\u20131738","journal-title":"Leukemia"},{"key":"6031_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/10428194.2020.1855345","volume":"62","author":"C Geng","year":"2021","unstructured":"Geng C, Yang G, Wang H et al (2021) Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leuk Lymphoma 62:883\u2013890","journal-title":"Leuk Lymphoma"},{"key":"6031_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ejh.12728","volume":"97","author":"R S\u00f8rrig","year":"2016","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M et al (2016) Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol 97:303\u2013309","journal-title":"Eur J Haematol"},{"key":"6031_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT et al (2020) Measurable residual disease by Next-Generation Flow Cytometry in multiple myeloma. J Clin Oncol 38:784\u2013792","journal-title":"J Clin Oncol"},{"key":"6031_CR13","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","volume":"20","author":"H Avet-Loiseau","year":"2020","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O et al (2020) Minimal residual Disease Status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a Meta-analysis. Clin Lymphoma Myeloma Leuk 20:e30\u2013e37","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6031_CR14","unstructured":"D\u00edaz-Rodr\u00edguez R, F\u00e9rnandez-Gonz\u00e1lez M, Mart\u00edn-Mart\u00edn A, XXIX National Congress of SETH, Sevilla (2013) Resoluci\u00f3n de la inmunoparesia como par\u00e1metro de la remisi\u00f3n completa real en el mieloma m\u00faltiple. LV National Congress of SEHH and: CO-021. https:\/\/www.sehh.es\/comunicaciones-cientificas-de-los-congresos-sehh-seth-2000-2017\/lv-congreso-nacional-sehh-xxix-congreso-seth. Accesed November 7th, 2023"},{"key":"6031_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2016.158345","volume":"102","author":"V Gonz\u00e1lez-Calle","year":"2017","unstructured":"Gonz\u00e1lez-Calle V, Cerd\u00e1 S, Labrador J et al (2017) Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica 102:922\u2013931","journal-title":"Haematologica"},{"key":"6031_CR16","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1080\/10428194.2017.1403026","volume":"59","author":"VH Jimenez-Zepeda","year":"2018","unstructured":"Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N (2018) Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk Lymphoma 59:1920\u20131926","journal-title":"Leuk Lymphoma"},{"key":"6031_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cancers12010012","volume":"12","author":"S Ozaki","year":"2019","unstructured":"Ozaki S, Harada T, Yagi H et al (2019) Polyclonal Immunoglobulin Recovery after autologous stem cell transplantation is an independent prognostic factor for Survival Outcome in patients with multiple myeloma. Cancers (Basel) 12:12","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6031_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-018-3574-4","volume":"98","author":"W Gao","year":"2019","unstructured":"Gao W, Li J, Wu Y et al (2019) Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation. Ann Hematol 98(5):1177\u20131184","journal-title":"Ann Hematol"},{"key":"6031_CR19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00277-020-04068-5","volume":"99","author":"C Eisfeld","year":"2020","unstructured":"Eisfeld C, E\u00dfeling E, Wullenkord R et al (2020) Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol 99:1907\u20131915","journal-title":"Ann Hematol"},{"key":"6031_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bjh.18182","volume":"198","author":"J D\u00e1vila","year":"2022","unstructured":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F et al (2022) Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival. Br J Haematol 198:278\u2013287","journal-title":"Br J Haematol"},{"key":"6031_CR21","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen Z, Cao J et al (2024) Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis. Hematology. Epub 2024 Mar 12.","DOI":"10.1080\/16078454.2024.2329378"},{"issue":"6","key":"6031_CR22","first-page":"1909","volume":"109","author":"S Lakhwani","year":"2024","unstructured":"Lakhwani S, Rosi\u00f1ol L, Puig N et al (2024) Recovery of uninvolved heavy\/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica 109(6):1909\u20131917","journal-title":"Haematologica"},{"key":"6031_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"6031_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","volume":"127","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Mart\u00ednez-L\u00f3pez J, Hern\u00e1ndez MT et al (2016) Sequential vs alternating administration of VMP and rd in elderly patients with newly diagnosed MM. Blood 127:420\u2013425","journal-title":"Blood"},{"key":"6031_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1515\/CCLM.2007.069","volume":"45","author":"X Fuentes-Arderiu","year":"2007","unstructured":"Fuentes-Arderiu X, Alonso-Gregorio E, Alvarez-Funes V et al (2007) Multicentre physiological reference intervals for serum concentrations of immunoglobulins a, G and M, complement C3c and C4 measured with Tina-Quant reagents systems. Clin Chem Lab Med 45:387\u2013390","journal-title":"Clin Chem Lab Med"},{"key":"6031_CR26","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Cedena MT, Puig N et al (2016) Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 127:3165\u20133174","journal-title":"Blood"},{"key":"6031_CR27","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB et al (2017) Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol 35:2900\u20132910","journal-title":"J Clin Oncol"},{"key":"6031_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2013.084350","volume":"98","author":"N Tovar","year":"2013","unstructured":"Tovar N, de Larrea CF, Ar\u00f3stegui JI et al (2013) Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica 98:1142\u20131146","journal-title":"Haematologica"},{"key":"6031_CR29","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood.2021012319","volume":"138","author":"A Jim\u00e9nez-Ubieto","year":"2021","unstructured":"Jim\u00e9nez-Ubieto A, Paiva B, Puig N et al (2021) Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: are these times of change? Blood 138:1901\u20131905","journal-title":"Blood"},{"key":"6031_CR30","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06031-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06031-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:11:23Z","timestamp":1735848683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06031-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6031"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06031-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4797880\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review board or independent ethics committee of each participating center approved the study. This trial was registered at\n                      \n                      with the number #NCT01237249.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}